| Literature DB >> 33533079 |
Stephanie Best1,2, Janet Long1, Tahlia Theodorou1, Sarah Hatem1, Rebecca Lake1, Alison Archibald3,4,5, Lucinda Freeman6,7, Jeffrey Braithwaite1.
Abstract
BACKGROUND: As interest in reproductive genetic carrier screening rises, with increased availability, the role of healthcare practitioners is central in guiding uptake aligned with a couples' values and beliefs. Therefore, practitioners' views on implementation are critical to the success of any reproductive genetic carrier screening programme. AIM: To explore healthcare practitioners' perceptions of the barriers and enablers to implementation. MATERIALS &Entities:
Mesh:
Year: 2021 PMID: 33533079 PMCID: PMC8252081 DOI: 10.1002/pd.5914
Source DB: PubMed Journal: Prenat Diagn ISSN: 0197-3851 Impact factor: 3.050
Inclusion and exclusion criteria for articles
| Inclusion criteria | Exclusion criteria |
|---|---|
| Peer‐reviewed empirical research | Opinion pieces, comments, editorials, etc. (not empirical research) |
| Reproductive genetic carrier screening | Other prenatal screening, e.g., NIPT/chromosomal |
| Humans | Animal models |
| Implementation or preimplementation of screening programs in a ‘real world’ context | Nonclinical research without a link to a clinical ‘real‐world’ context (e.g., studies investigating which conditions to be included in reproductive carrier screening panels) |
| Focus is on health care practitioners' attitudes, in the context of identifying barriers and enablers to implementation | Focus not on health care practitioners' attitudes |
| Health practitioners engaged with reproductive genetic carrier screening | General public and client views |
Abbreviation: NIPT, noninvasive prenatal test.
FIGURE 1PRISMA flow diagram. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta‐Analyses
Characteristics of final full text articles included
| References | Country | Condition(s) screened | Aim | Methodology | Participants |
|---|---|---|---|---|---|
| Archibald et al. | Australia | Fragile X | To explore the attitudes of health practitioners, relatives of people with fragile X syndrome, potential target populations for carrier screening (pregnant and nonpregnant women), and the general community regarding population‐based carrier screening for fragile X syndrome. | Interviews and focus groups | Both primary and secondary health care providers |
| Archibald et al. | Australia | Fragile X | To explore stakeholder views about offering population‐based genetic carrier screening for fragile X syndrome. | Interviews and focus groups | Both primary and secondary health care providers, including genetic professionals |
| Baars et al. | The Netherlands | Cystic fibrosis (CF) | To investigate genetic knowledge and genetic testing among general practitioners (GPs), gynaecologists (GYNs) and paediatricians in the Netherlands. | Surveys | Both primary and secondary health care providers, including genetic professionals |
| Benn et al. | USA | Expanded | To assess the opinions of fellows of the American College of obstetricians and GYNs on expanded carrier testing and noninvasive prenatal testing. | Surveys | Secondary |
| Briggs et al. | USA | Expanded | To assess current practice utilisation and attitudes regarding the implementation of expanded carrier screening (ECS) into clinical practice. | Surveys | Secondary |
| Cho et al. | USA | Expanded | To clarify genetic practitioners' views on the potential benefits and challenges of ECS. To solicit advice from genetics practitioners regarding how best to integrate ECS into preconception reproductive healthcare. | Focus groups | Secondary—genetic professionals |
| Cousens et al. | Australia | β‐Thalassaemia | To gain a better understanding of healthcare practitioners' practice and attitudes regarding prenatal β‐thalassaemia carrier screening in Australia. | Interviews | Both primary and secondary health care providers, including genetic professionals |
| Cunningham et al. | Australia | CF | To investigate the attitudes of healthcare practitioners caring for patients with CF toward population‐based carrier screening for CF. | Surveys | Primary |
| Darcy et al. | USA | CF | To determine the current awareness by obstetricians of the existence and content of practice guidelines, the variety in practice regarding CF carrier screening, and the level of knowledge regarding CF genetics and screening result interpretation. To explore potential barriers to offering screening and whether academic affiliation or type of practice influences outcome. | Surveys | Secondary |
| Delgado et al. | USA | Preconception genetic screening | To assess provider knowledge, comfort with counselling, formal training and educational needs regarding prenatal genetic screening and diagnostic testing. | Surveys | Secondary, including genetic professionals |
| Holtkamp et al. | The Netherlands | Expanded | To identify general and population‐specific barriers and needs reflected by Dutch stakeholders regarding the implementation of (expanded universal) carrier screening. | Interviews | Both primary and secondary health care providers, including genetic professionals |
| Janssens et al. | Belgium | Expanded | To explore attitudes of clinical and molecular geneticists about the implementation of multidisease or ECS for monogenic recessive disorders. | Interviews | Secondary—genetic professionals |
| Janssens et al. | Belgium | Expanded | To explore European geneticists' attitudes towards ECS, focussing on their concrete suggestions and recommendations for the use of ECS in the clinical setting. | Interviews | Secondary—genetic professionals |
| Lazarin et al. | USA | Expanded | To conduct an extensive survey in a large genetic counsellor population on personal and practitioner attitudes regarding ECS. | Surveys | Secondary—genetic professionals |
| Matar et al. | Sweden | Expanded | To explore and describe Swedish healthcare practitioners' perceptions of preconception ECS with focus on the ethical aspects. | Interviews | Secondary, including genetic professionals |
| McClaren et al. | Australia | CF | To explore whether or not CF carrier screening should be offered in the Australian setting, the best time for offering carrier screening, the information required for making a decision about carrier screening, and how this information can best be provided. | Interviews and focus groups | Both primary and secondary health care providers |
| Morgan et al. | USA | CF | To increase understanding of when, how, and in what populations obstetrician‐GYNs are implementing the published guidelines for CF carrier screening and to learn the physicians' opinions and practices regarding CF screening. | Surveys | Secondary |
| Morgan et al. | USA | CF | To assess the impact of self‐reported familiarity with published guidelines on knowledge, implementation, and opinions of obstetrician–GYNs regarding carrier screening for CF. | Surveys | Secondary |
| Poppelaars et al. | The Netherlands | CF | (1) To investigate the attitude of potential providers (GPs and MHS workers) and the target population (couples planning a pregnancy) towards a CF carrier screening programme; (2) to investigate opinions regarding the preferred method of implementation; (3) to determine the role of GPs and MHS workers in the screening and pre‐test education, and (4) to determine the support needed. | Surveys | Both primary and secondary health care providers |
| Poppelaars et al. | The Netherlands | CF | To explore the possibilities and barriers in the implementation of a nationwide preconceptional CF carrier screening programme in The Netherlands. | Focus groups | Both primary and secondary health care providers |
| Poppelaars et al. | The Netherlands | CF | To investigate the attitudes of GPs and CHS workers with regard to routinely offering preconceptional CF carrier screening, and to identify variables which were associated with a positive and a negative attitude. | Surveys | Both primary and secondary health care providers |
| Qureshi et al. | UK | CF and thalassaemia | To assess GPs' confidence in their ability to provide initial prenatal advice for couples carrying common autosomal recessive disorders (either the CF or thalassaemia gene), and their opinions of different approaches for referral to prenatal diagnostic services for such at‐risk couples. | Surveys | Primary |
| Schuurmans et al. | The Netherlands | Expanded | To investigate whether test‐provision by GPs could be a feasible approach for ECS and result in informed choice of couples who attended pretest counselling. | Checklist and interviews | Primary |
| Stark et al. | Australia | General including β‐ thalassaemia, CF and fragile X | To gather information about the current practice and attitudes of Australian obstetricians toward carrier screening for genetic conditions as part of routine pregnancy care. | Surveys | Secondary |
| Tsianakas et al. | UK | Sickle cell disease and thalassaemia | To assess the feasibility of offering antenatal SC&T screening in primary care at the time of pregnancy confirmation. | Interviews | Primary |
| Valente et al. | Australia | CF | To explore the opinions, knowledge and practice patterns of GPs, obstetricians and fertility specialists in Victoria, Australia. | Survey | Both primary and secondary health care providers |
Abbreviations: CHS, Community health service; MHS, Municipal health services; SC&T, sickle cell and thalassaemia.
Themes and subthemes identified with papers referring to themes. Key: Papers referring to expanded reproductive carrier screening are prefixed with E, papers with a focus on the subtheme are underlined
| Theme | Subtheme | Papers |
|---|---|---|
|
The use and potential impact of reproductive genetic carrier screening | Achieving equitable service provision, including cost to the individual | Archibald (2016) |
| Potential impact (including the offer) on the client, including concern about client anxiety, informed choice and stigma | Archibald (2012) | |
|
Practitioner beliefs and expectations about the process of delivering reproductive genetic carrier screening | Practitioner attitudes to and beliefs about RGCS | Archibald (2012) |
| Practitioner perceptions of their ability to deliver RGCS including client selection, interpreting results and confidence | Archibald (2012) | |
| Practitioner knowledge and support required to deliver RGCS | Cousens (2014) | |
| Practitioner expectations and external views influencing their clinical decision making including the impact of their recommendations, professional bodies, legal expectations | E Benn (2014) | |
|
Resources available for practitioners for reproductive genetic carrier screening | Provision of counselling including genetic counsellors and other professionals | Darcy (2011) |
| Variation in potential models of service provision including who provides RGCS and when | Archibald (2012) | |
| Nonclinical resource barriers including strategic costs, responsibility, time | Archibald (2012) |
Note: Papers referring to expanded reproductive carrier screening are prefixed with E, papers with a focus on the subtheme are underlined.
Abbreviation: RGCS, reproductive genetic carrier screening.
FIGURE 2Themes identified from the literature review, demonstrating interconnectedness
FIGURE 3Barriers (yellow) linked with potential enablers (white), identified from the literature – pink boxes indicate no enabler was noted in the literature. Further details can be found in supplementary file